Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
Part of Cancer clinical trials.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 18 to 75
- You have confirmed HER2-positive invasive breast cancer (a biopsy showed this)
- Your cancer is stage II or III, and you have not started any cancer treatment yet
- Your overall health/activity level is ECOG 0–1 (you can do most daily activities)
- Your kidneys, liver, and other organs work well enough for study drugs
- You must not have received any prior anti-cancer treatment (chemo, radiation, targeted pills, or hormone/endocrine therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a new combination of two targeted drugs (SHR-A1811 and pyrotinib) for HER2-positive breast cancer that has spread or is locally advanced and has grown despite previous treatments. The goal is to see if this combination can shrink tumors and slow the cancer's growth.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.